张信红,钟光林,裴保香,刘屏.国产与进口头孢哌酮的药物经济学研究[J].中华流行病学杂志,1999,20(6):357-359 |
国产与进口头孢哌酮的药物经济学研究 |
Study on the pharmacoeconomics between imported and domestic cefoperazone |
收稿日期:1999-08-08 出版日期:2014-09-16 |
DOI: |
中文关键词: 头孢哌酮 药物经济学 药代动力学 |
英文关键词: Cefoperazone Pharmacoeconomics Pharmacokinetics |
基金项目: |
|
摘要点击次数: 2759 |
全文下载次数: 1203 |
中文摘要: |
目的 对国产与进口头孢哌酮进行药物经济研究。方法 高效液相色谱法测定两药的人体药代动力学参数,临床观察两药治疗肺部感染患者的疗效、细菌清除、药物不良反应及治疗费用。应用成本- 效果分析法分析成本效果比。结果 两药的体内药代动力学过程基本一致,临床有效率、细菌清除和不良反应的差异不明显,两药的成本效果比及治疗费用差别显著。结论国产头孢哌酮的作用与进口头孢哌酮无明显差异,但在成本和价格上有显著优势 |
英文摘要: |
Objective By evaluating the pharmacokinetics and clinical therapeutic effectiveness, ADRs and clinical expenses, both Imported and Domestic Cefoperazone were compared. Methods Clinical therapeutic effectiveness, abnormal drug reaction (ADR) and clinical expenses of imported Cefoperazone were compared with that of domestic product. Both of the two drugs' pharmacokinetics were also studied by HPLC. Result Both products did not show significant differences in pharmacokinetics, therapeutic effectiveness and bactericidal power. However, the domestic product had more ADR than the imported ones and the clinical expenses of domestic Cefoperazone was significantly lower than the imported ones. Conclusion It is a safe, rational, economic choice to replace the imported Cefoperazone with the domestic product. |
查看全文
Html全文
查看/发表评论 下载PDF阅读器 |
|
关闭 |